Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC
Naidoo, J. Antonia, S. J. Wu, Y. L. Cho, B. C. Thiyagarajah, P. Mann, H. Newton, M. D. Faivre-Finn, Corinne
Naidoo, J.
Antonia, S. J.
Wu, Y. L.
Cho, B. C.
Thiyagarajah, P.
Mann, H.
Newton, M. D.
Faivre-Finn, Corinne
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Naidoo J, Antonia SJ, Wu YL, Cho BC, Thiyagarajah P, Mann H, et al. Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680302143.